Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boston Children's Hospital
With
Glaser Pediatric Research Network
Elizabeth Glaser Pediatric AIDS Foundation
Age
1–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligible patients will be \> 1 and ≤ 21 years old.
All patients must be receiving chemotherapy that includes doxorubicin administered as an infusion of any duration \< 24 hours, on either a 1-day or 2-day schedule. This includes bolus and all short infusion schedules.
All patients or their parents/legal guardians will provide informed consent/assent (as required by law) indicating their awareness of the investigational nature and the risks of this study according to the informed consent process.
You may not be if
Women who are known to be pregnant or lactating
Patients with significant uncontrolled systemic illness
Serum glutamic oxaloacetic transaminase (SGOT/AST), serum glutamic pyruvate transaminase (SGPT/ALT) \> 3 times the upper limit of normal tested within 14 days prior to infusion
Bilirubin \> the upper limit of normal tested within 14 days prior to infusion
Patients whose dose of doxorubicin is based on ideal body weight
Patients who weigh \< 12 kilograms at time of screening